Editorial: Liver diseases and programmed cell death

Peng Cao; Yongyi Liang; Yi Wang; Chao Mao; Weijia Wang; Sha Li; Lianxiang Luo

doi:10.3389/fphar.2023.1182013

Editorial: Liver diseases and programmed cell death

Front Pharmacol. 2023 Mar 28:14:1182013. doi: 10.3389/fphar.2023.1182013. eCollection 2023.

Authors

Peng Cao¹, Yongyi Liang², Yi Wang³, Chao Mao⁴, Weijia Wang⁵, Sha Li⁶, Lianxiang Luo⁷

Affiliations

¹ Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
² The First Clinical College, Guangdong Medical University, Zhanjiang, China.
³ Department of Critical Care Medicine, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu, China.
⁴ Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
⁵ State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian, China.
⁶ School of Public Health, Shanghai Jiao Tong University, Shanghai, China.
⁷ The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, China.

No abstract available

Keywords: alcohol-related liver disease; drug induced liver injury; hepatocellular carcinoma; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; programmed cell death.

Publication types

Editorial